Power3 Medical Products, Inc. (PWRM.OB)
Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer's and Parkinson's, to name a few.
In addition, Power3 is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by Power3 several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash. Because current management believes these toxic debt instruments are responsible for Power3's depressed stock price and have distracted the company from its mission, Power3 plans to settle as many of these nagging lawsuits as possible prior to the completion of its merger with Rozetta-Cell Life Sciences, Inc. As for those lawsuits that cannot be speedily resolved, Power3 will continue to rigorously defend its position. For example, one such lawsuit involves Neogenomics, Inc., which was recently granted a motion for summary judgment with respect to an amount due under a convertible debenture. Power3 intends to appeal this decision.
"We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now," stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. "We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger."
Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.
International, breast cancer consists 10% of all cancer incidence among the ladies, defining it as the most frequent kind of non-skin cancer in females and also the 5th most popular grounds for cancer death. In 04, cancer of the breast caused 519,000 fatalities world-wide (7% associated with cancer deaths; almost 1% of all deaths). Cancer of the breast is about a hundred times more established in women compared to men, although men are apt to have poorer success on account of waiting times in medical diagnosis.
Orofino Gold Corp. (PINK OTC: ORFG) has numerous Gold development properties in Colombia, a current hot spot of gold production in the world markets.
The company is please to announce that the Board Of Directors have appointed Mr. Ning Shi Long as Chairman of the Board and Executive Director.
Mr. Ary Fernando Pernett Marque has been appointed as the new President/CEO & Executive Director of Orofino Gold Corp. (see full resume on the company website at www.orofinogold.com)
Mr. Pernett will be responsible for all affairs of the Company in Colombia. Mr. Pernett has 30 years of experience working in the Colombian Mining sector and will over the near term choose his new development team to assist in the development of the company's Senderos de Oro gold camp in the Sur de Bolivar Colombia.
The company and Mr. Pernett will continue to work with Contexto Legal of Medellin and Bogota, the company's legal counsel as well as Discovery Consultants, (The Qualified 43-101 team) Canada, as they have in the past. The new team will now aggressively pursue other known Gold occurrences in the companies Senderos de Oro Gold Camp while the development team works to improve production at La Azul Mine.
The Board of Director's have accepted resignation of John T. Martin, former Managing Director of the Company. His resignation is effective immediately. The Company wish him well and success in future endeavors.
Hughes Communications, Inc. (Nasdaq:HUGH) the global leader in broadband satellite networks and services, and a leading provider of managed network and application services, announced its managed Voice-over-IP (VoIP) solution for the government market. Using the new Hughes ActiveQoS technology, Hughes can provide superior voice quality over affordable broadband, eliminating the need for agencies to invest in expensive, leased line Multiprotocol Label Switching (MPLS) networks. Hughes ActiveQoS technology is integrated into the customer equipment onsite and actively monitors and adapts to network congestion over the broadband network.
Hughes Communications, Inc., through its subsidiary, Hughes Network Systems, LLC, provides broadband satellite network services and systems. It delivers broadband Internet services, including satellite-based Internet access, technical support, multiple email accounts, professional standard installation, and a commercial-grade antenna.
Microchip Technology Inc. (Nasdaq:MCHP) a leading provider of microcontroller, analog and Flash-IP solutions, announced a new, six-member family of 32-bit PIC32MX5/6/7 microcontrollers that provides the same integrated Ethernet, CAN, USB and serial connectivity peripherals with new, more cost-effective memory options. Additionally, design enhancements have been made that provide lower power consumption of 0.5 mA/MHz active current, higher Flash memory endurance of 20k read/write cycles and better EEPROM emulation capability. And, by maintaining common pin outs, the PIC32 portfolio provides designers with a seamless migration path to achieve the correct balance of memory and cost for their high-performance applications.
Microchip Technology Incorporated, together with its subsidiaries, develops, manufactures, and sells semiconductor products for various embedded control applications.
ASML Holding NV (Nasdaq:ASML) announced 2010 fourth quarter and full year results according to US GAAP as follows: Q4 2010 net sales of EUR 1,521 million versus Q3 2010 net sales of EUR 1,176 million (Q4 2009 net sales of EUR 581 million). Full year 2010 net sales were EUR 4,508 million, up 182.4 percent versus 2009 net sales of EUR 1,596 million. Q4 2010 net income of EUR 407 million, or 26.7 percent of net sales, versus a Q3 2010 net income of EUR 269 million, or 22.8 percent of net sales (Q4 2009 net income of EUR 50 million or 8.7 percent of net sales). Full year 2010 net income amounted to EUR 1,022 million or 22.7 percent of net sales, compared with 2009 net loss of EUR 151 million or 9.5 percent of net sales. Q4 2010 net bookings of EUR 2,315 million (see page 3), with 117 systems including 104 new and 13 used systems, leading to a systems backlog valued at EUR 3,856 million as of December 31, 2010.
ASML Holding N.V., through its subsidiaries, engages in designing, manufacturing, marketing, and servicing semiconductor processing equipment used in the fabrication of integrated circuits.
Sign up for free stock alerts at http://www.pennygovernance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more @ http://pennygovernance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings Inc. (CRWE.OB) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising.